Mathilde Jalving

20PUBLICATIONS
112CO-AUTHORS
Environmental assessment and monitoringMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersCancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (20)

|Sep 17, 2026
Towards appropriate guidance for the ethical challenges of environmentally sustainable prescribing.

|Sep 10, 2026
Programmed death ligand 1 (PD-L1) PET/CT imaging to evaluate tumour saturation during atezolizumab treatment.

|Feb 27, 2026
Correction: Govaerts et al. Incidence and Clinical Features of Pseudoprogression in Brain Metastases After Immune-Checkpoint Inhibitor Therapy: A Retrospective Study. Cancers 2025, 17, 2425.

Chris W Govaerts, Miranda C A Kramer, Ingeborg Bosma

|Sep 10, 2025
Upfront whole blood transcriptional patterns in patients receiving immune checkpoint inhibitors associate with clinical outcome.

S Hone Lopez, S Loipfinger, A Bhattacharya

|Aug 14, 2025
Incidence and Clinical Features of Pseudoprogression in Brain Metastases After Immune-Checkpoint Inhibitor Therapy: A Retrospective Study.

Chris W Govaerts, Miranda C A Kramer, Ingeborg Bosma

|May 05, 2025
Evaluation of BRCA1/2 testing rates in epithelial ovarian cancer patients: lessons learned from real-world clinical data.

Lieke Lanjouw, Claire J H Kramer, Arja Ter Elst

Pageof 4

Frequent Collaborators

4 joint publications

Geertruida H de Bock

2 joint publications

Rudolf S N Fehrmann

2 joint publications

Karlijn P M Suijkerbuijk

2 joint publications

Michel W J M Wouters